February 20, 2021
Treatment of Stage IV- Metastatic or Recurrent Colon Cancer BookmarkGeorge Lundberg, MD
This CancerConnect article summarizes the latest treatment options for stage IV colorectal cancer.
August 22, 2018
Bevacizumab and Temozolomide in First Recurrence of Glioma Without 1p/19q Codeletion BookmarkEmma Shtivelman, PhD
Excerpt from The ASCO Post:
“In a phase II trial funded by the European Organisation for Research and Treatment of Cancer and reported in The Lancet Oncology, van den Bent et al found no evidence of a survival benefit with the addition of bevacizumab (Avastin) to temozolomide in patients with a first recurrence of World Health Organization grade II or III glioma without the 1p/19q codeletion.
“In the open-label trial, conducted at 32 European centers, 155 patients were randomized between February 2011 and July 2015 to receive either temozolomide at 150 to 200 mg/m² on days 1 to 5 every 4 weeks for a maximum of 12 cycles (n = 77) or the same temozolomide regimen plus bevacizumab at 10 mg/kg every 2 weeks until disease progression (n = 78). Previous chemotherapy must have been stopped at least 6 months before enrollment, and radiotherapy, at least 3 months before enrollment. Overall, 44% of patients in the combination group and 47% in the temozolomide group had grade III disease.”
Go to full article published by The ASCO Post on Aug 20, 2018.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.